Meeting Overview
Drury Lane Oakbrook Terrace
14.75 AMA Category 1, AAFP, 14.75 AANP
A Fresh Look at the Real-World Challenges
of Primary Care
Pri-Med Updates is designed to reflect the practitioner's patient appointment schedule. The curriculum is composed of 11 different symposia, each focused on a specific clinical condition and each presented by nationally-recognized speakers. Sessions include didactic presentations as well as interactive, case-based learning opportunities. The goal is to connect current research and leading opinion to insights you can put into practice at once, while enabling you to earn a maximum of 14.75 AMA PRA Category 1 Credit(s)TM or AANP contact hours of continuing education at no cost.
Customize your own schedule.
Come for 1 session, 1 day or all 11 sessions.
|
|
|
Goals and Objectives
Attend this continuing education activity and you will be able to:
- Earn up to 14.75 AMA PRA Category 1 Credit(s)TM or AANP contact hours of continuing education.
- Network with colleagues who live and practice in your area.
- Take advantage of complimentary world-class continuing medical education.
- Interact with expert faculty during dedicated Q&A throughout the program.
- Test your knowledge and receive immediate feedback on patient care scenarios using an Audience Response System.
This activity is intended for primary care providers currently engaged in patient care.
Find additional Pri-Med educational programs in your area.
Marketing Partners
Pri-Med partners with local healthcare associations, managed care organizations, and publications in order to ensure that all practicing clinicians have the opportunity to attend. Pri-Med would like to thank the following partners for this program to date:
Aetna, American Society of Hypertension, Inc., and Illinois Academy of Family Physicians.
Educational Grants
To date, the following organizations have provided educational grants in support of this Pri-Med activity:
Abbott,
Eli Lilly & Company,
Forest Pharmaceuticals, Inc.,
GlaxoSmithKline,
Merck & Co., Inc.,
Novartis Pharmaceuticals Corporation,
Novo Nordisk Inc. ,
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.,
and Takeda Pharmaceuticals North America, Inc..